Panacea Biotec Limited has submitted a regulatory compliance filing to stock exchanges regarding the newspaper publication of a notice for opening a special window for transfer and dematerialization of physical shares. The filing demonstrates the company's adherence to SEBI regulatory requirements for shareholder communication.

Regulatory Compliance Details

The compliance filing was submitted under Regulation 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The notice was published on April 15, 2026, following SEBI Circular No. HO/38/13/11(2)2026-MIRSD-POD/I/3750/2026 dated January 30, 2026.

Publication Details

The notice regarding the special window for transfer and dematerialization of physical shares was published in two newspapers to ensure wide reach among shareholders:

• Financial Express (English daily)
• Desh Sewak (Punjabi daily)

This dual-language publication approach ensures compliance with regulatory requirements while reaching shareholders across different linguistic preferences.

Stock Exchange Communication

The filing was simultaneously submitted to both major Indian stock exchanges where Panacea Biotec shares are listed:

The communication was signed by Ankit Jain, General Manager- Legal & Company Secretary, and digitally signed on April 15, 2026, at 14:36:05 +05'30'.

Special Window Purpose

The special window initiative is designed to facilitate shareholders holding physical share certificates in transferring and dematerializing their holdings. This process helps shareholders convert their physical certificates into electronic form, making trading and transfer processes more efficient and secure.

The regulatory filing ensures transparency and keeps all stakeholders informed about the company's compliance with SEBI guidelines regarding shareholder services and communication requirements.

Panacea Biotec Limited has announced receiving a Letter of Award from the Central Medical Services Society (CMSS), Ministry of Health and Family Welfare, Government of India, for the supply of Diphtheria and Tetanus Vaccine worth ₹20.79 crore. The Letter of Award was dated April 10, 2026, and the company disclosed this development under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Contract Details and Specifications

The contract involves the supply of Diphtheria and Tetanus Vaccine (Absorbed) for Adults and Adolescents IP, commonly referred to as Td Vaccine. The supply will be executed in several tranches over an extended period, demonstrating the scale and importance of this government contract.

Execution Timeline and Supply Schedule

The vaccine supply is scheduled to commence from September 2026 and will continue until December 2028, spanning over two years. This extended timeline indicates a substantial and sustained supply commitment that will contribute to the company's revenue stream over the contract period. The phased delivery approach in several tranches allows for systematic distribution and quality management throughout the contract duration.

Regulatory Compliance and Disclosure

Panacea Biotec has fulfilled all regulatory disclosure requirements under SEBI LODR Regulations. The company confirmed that this is a domestic contract with no related party transactions involved. Additionally, the promoter/promoter group/group companies have no interest in the entity that awarded the contract, ensuring transparency in the business relationship.

Strategic Significance

This government contract represents a significant business development for Panacea Biotec's vaccine division. The award from CMSS, a key government procurement agency for medical supplies, validates the company's manufacturing capabilities and regulatory compliance standards. The contract strengthens Panacea Biotec's position in the domestic vaccine market and demonstrates the government's confidence in the company's ability to deliver quality pharmaceutical products for public health programs.